Fresh Tracks con­sid­ers op­tions to stay afloat and de­vel­op au­toim­mune can­di­dates

Fresh Tracks Ther­a­peu­tics is out with Phase I da­ta on its atopic der­mati­tis can­di­date, FRTX-02. But to con­tin­ue de­vel­op­ment, the clin­i­cal-stage biotech is con­sid­er­ing a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER